Extension of strategic alliance with Summit
Summit Therapeutics and Oxford have announced a multi-year extension of their strategic alliance for the development of utrophin modulators to treat Duchenne Muscular Dystrophy.
We publish news of technology innovations, investment opportunities, together with updates from spin-out & start-up companies and licensees
Summit Therapeutics and Oxford have announced a multi-year extension of their strategic alliance for the development of utrophin modulators to treat Duchenne Muscular Dystrophy.
Perspectum announced today it has been given US FDA clearance to market its test for diagnosing and measuring liver disease.
Oxford University Innovation spinout OrganOx has received CE mark certification for its OrganOx metra device, which improves the success of liver transplantation.
Outside London, it is arguable that no other region has had more of an effect on the evolution of the UK than Oxford. From custodians of the English language to leaders of the country, Oxford has continued to have a major impact on the shape and destiny of the British people.
Oxford University Innovation spinout NightstaRx Ltd (“Nightstar”), a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, has announced a $35 million Series B financing round.
Outstanding achievement in the UK Life Sciences sector is celebrated in the annual OBN Awards ceremony. Five spin-outs from Oxford featured in this year’s awards, presented on 1st October.